Table 1 Comparison of clinical characteristics between the three groups.
From: Gross hematuria after COVID-19 mRNA vaccination and kidney function trajectory in IgA nephropathy
Characteristics | Overall (n = 441) | Unvaccinated group (n = 25) | Vaccinated without GH group (n = 391) | Vaccinated with GH group (n = 25) | p-value |
|---|---|---|---|---|---|
Age; years | 51 [42–62] | 51 [44–60] | 52 [42–63] | 46 [32–54] | 0.037 |
Female; n (%) | 247 (56) | 14 (56) | 213 (55) | 20 (80) | 0.045 |
BMI; kg/m2 | 22.5 [20.1–24. 8] | 21.9 [19.6–24.4] | 22.5 [20.2–24.8] | 21.1 [18.2–23.9] | 0.100 |
History of IgA nephropathy: years | 12 [5–21] | 14 [4–21] | 12 [5–21] | 5 [2–12] | 0.008 |
History of GH before COVID-19 mRNA vaccination; n (%) | 163/403 (41) | - | 148/376 (39.4) | 15/25 (60) | 0.068 |
Hypertension; n (%) | 182 (44) | 13 (52) | 162 (41) | 7 (28) | 0.222 |
Diabetes; n (%) | 30 (7) | 1 (4) | 29 (7) | 0 (0) | 0.306 |
eGFR; mL/min/1.73 m2 | 57 [43–73] | 45 [26–71] | 57 [43–73] | 71 [60–84] | < 0.001 |
UPCR; g/gCr | 0.24 [0.08–0.67] | 0.54 [0.19–0.92] | 0.24 [0.08–0.62] | 0.42 [0.10–0.83] | 0.015 |
Hematuria grade | < 0.001 | ||||
0–4 RBC/HPF; n (%) | 311 (71) | 18 (72) | 288 (74) | 5 (20) | |
5–19 RBC/HPF; n (%) | 76 (17) | 3 (12) | 64 (16) | 9 (36) | |
20–49 RBC/HPF; n (%) | 30 (7) | 3 (12) | 23 (6) | 4 (16) | |
50–many RBC/HPF; n (%) | 24 (5) | 1 (4) | 16 (4) | 7 (28) | |
Serum IgA; mg/dL | 269 [204–361] | 288 [238–352] | 272 [201–363] | 250 [200–289] | 0.528 |
Serum C3; mg/dL | 99 [87–113] | 100 [92–111] | 99 [87–114] | 91 [83–104] | 0.244 |
RAASi use; n (%) | 325 (74) | 23 (92) | 296 (76) | 16 (64) | 0.064 |
Corticosteroid use; n (%) | 240 (54) | 17 (68) | 212 (54) | 11 (44) | 0.228 |
Tonsillectomy; n (%) | 166 (38) | 10 (40) | 149 (38) | 7 (28) | 0.420 |
